Latest news with #AbilityBiotherapeutics
National Post
3 days ago
- Business
- National Post
Ability Biotherapeutics Welcomes Angèle Maki, PhD to its Board of Directors
Article content MONTREAL — Ability Biotherapeutics, a biotechnology leader focused on developing next-generation antibody therapies, is pleased to announce the appointment of Angèle Maki, PhD to its Board of Directors. Article content Article content Dr. Maki brings over 20 years of experience in the biopharmaceutical industry, with a distinguished track record of leadership in business development and strategic partnerships across both emerging biotech ventures and global pharmaceutical companies. She currently serves as Chief Business Officer at Callio Therapeutics, a company realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. Article content Over the course of her career, Dr. Maki has held senior roles at leading organizations including Medarex (acquired by Bristol Myers Squibb), Bristol Myers Squibb, Genentech, Merck & Co., Eli Lilly, ReCode Therapeutics, and Hummingbird Bioscience which spun out Callio Therapeutics. She has led and executed a broad spectrum of transactions across modalities and therapeutic areas—from early research collaborations to therapeutic licensing agreements and acquisitions—and played a key role in the venture strategy while at Eli Lilly. Article content 'We are thrilled to welcome Angèle to our Board of Directors at this pivotal stage in Ability's growth,' said Giles Day, Chief Executive Officer of Ability Biotherapeutics. 'Her deep experience in business development, licensing, and strategic partnerships across both biotech and pharma will be invaluable as we advance our lead antibody programs toward preclinical development and prepare for our first human clinical trials. As Ability continues to build momentum, Angèle's insights and leadership will help guide us through the critical decisions that lie ahead.' Article content In addition to her corporate roles, Dr. Maki is a passionate advocate for innovation and entrepreneurship. She currently serves as Board Chair of Canadian Entrepreneurs in Life Sciences (CELS), a non-profit organization supporting emerging leaders in the sector. Dr. Maki earned her Ph.D. in Biological Chemistry from Stanford University and holds a in Chemistry from the University of Winnipeg. Article content 'I'm truly delighted to join the Board of Directors at Ability Biotherapeutics,' said Dr. Maki. 'Ability's bold mission to revolutionize targeted antibody therapies for cancer and autoimmune diseases, combined with the team's scientific excellence and innovative spirit, makes it an incredibly exciting company to support. I look forward to contributing to its continued growth as it advances toward clinical development and strives to improve patient outcomes.' Article content About Ability Biotherapeutics Ability Biotherapeutics is the next-generation biotherapeutics company developing logic-gated antibodies with exceptional contextual selectivity and stability, driving safer, more effective immunotherapies for cancer and autoimmune diseases. Its proprietary platform, AbiLeap™, uses generative AI powered by one of the largest and exclusively held, therapeutically relevant human antibody databases, providing distinct insights for sequence space exploration. Combining AI with in vitro display and screening technologies, AbiLeap™ generates fully human antibodies that are conditionally activated and multi-specific, directing therapeutic targeting to specific cells and disease sites. This approach enables solutions for indications with high unmet clinical needs by reducing toxicity and significantly broadening the therapeutic window, maximizing treatment benefits. Ability's experienced team is committed to revolutionizing targeted therapeutics to transform patient outcomes and redefine industry standards. To learn more, visit their LinkedIn page, or contact them at partnering@ Article content Article content Article content Article content Contacts Article content Article content Article content
Business Wire
3 days ago
- Business
- Business Wire
Ability Biotherapeutics Welcomes Angèle Maki, PhD to its Board of Directors
MONTREAL--(BUSINESS WIRE)--Ability Biotherapeutics, a biotechnology leader focused on developing next-generation antibody therapies, is pleased to announce the appointment of Angèle Maki, PhD to its Board of Directors. Dr. Maki brings over 20 years of experience in the biopharmaceutical industry, with a distinguished track record of leadership in business development and strategic partnerships across both emerging biotech ventures and global pharmaceutical companies. She currently serves as Chief Business Officer at Callio Therapeutics, a company realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. Over the course of her career, Dr. Maki has held senior roles at leading organizations including Medarex (acquired by Bristol Myers Squibb), Bristol Myers Squibb, Genentech, Merck & Co., Eli Lilly, ReCode Therapeutics, and Hummingbird Bioscience which spun out Callio Therapeutics. She has led and executed a broad spectrum of transactions across modalities and therapeutic areas—from early research collaborations to therapeutic licensing agreements and acquisitions—and played a key role in the venture strategy while at Eli Lilly. 'We are thrilled to welcome Angèle to our Board of Directors at this pivotal stage in Ability's growth,' said Giles Day, Chief Executive Officer of Ability Biotherapeutics. 'Her deep experience in business development, licensing, and strategic partnerships across both biotech and pharma will be invaluable as we advance our lead antibody programs toward preclinical development and prepare for our first human clinical trials. As Ability continues to build momentum, Angèle's insights and leadership will help guide us through the critical decisions that lie ahead.' In addition to her corporate roles, Dr. Maki is a passionate advocate for innovation and entrepreneurship. She currently serves as Board Chair of Canadian Entrepreneurs in Life Sciences (CELS), a non-profit organization supporting emerging leaders in the sector. Dr. Maki earned her Ph.D. in Biological Chemistry from Stanford University and holds a in Chemistry from the University of Winnipeg. 'I'm truly delighted to join the Board of Directors at Ability Biotherapeutics,' said Dr. Maki. 'Ability's bold mission to revolutionize targeted antibody therapies for cancer and autoimmune diseases, combined with the team's scientific excellence and innovative spirit, makes it an incredibly exciting company to support. I look forward to contributing to its continued growth as it advances toward clinical development and strives to improve patient outcomes.' About Ability Biotherapeutics Ability Biotherapeutics is the next-generation biotherapeutics company developing logic-gated antibodies with exceptional contextual selectivity and stability, driving safer, more effective immunotherapies for cancer and autoimmune diseases. Its proprietary platform, AbiLeap™, uses generative AI powered by one of the largest and exclusively held, therapeutically relevant human antibody databases, providing distinct insights for sequence space exploration. Combining AI with in vitro display and screening technologies, AbiLeap™ generates fully human antibodies that are conditionally activated and multi-specific, directing therapeutic targeting to specific cells and disease sites. This approach enables solutions for indications with high unmet clinical needs by reducing toxicity and significantly broadening the therapeutic window, maximizing treatment benefits. Ability's experienced team is committed to revolutionizing targeted therapeutics to transform patient outcomes and redefine industry standards. To learn more, visit their LinkedIn page, or contact them at partnering@
National Post
29-04-2025
- Business
- National Post
Ability Biotherapeutics Moves to Inspire Bio Innovations in Montreal, Pioneering the New Generation of Targeted Antibodies
Article content MONTREAL — Ability Biotherapeutics, a Quebec-based leader in antibody therapeutics, is proud to announce its new location at Inspire Bio Innovations. The company will occupy the 6th floor of Phase 2 in the transformative redevelopment of the former Montreal Chest Institute, marking a significant step in its growth within Montreal's thriving life sciences ecosystem. Article content Article content The project's first phase is scheduled for completion this summer, with the second phase, including Ability's new space, expected to wrap up by the end of 2026. Ability Biotherapeutics is pioneering a new generation of targeted antibody therapies for cancer and autoimmune diseases, powered by its proprietary generative AI-based AbiLeap™ platform. Ability is advancing multiple drug discovery programs, with three lead programs now entering optimization and development as it prepares for preclinical studies. Taking advantage of Inspire Bio Innovations' dynamic environment, Ability plans to complete preclinical studies to demonstrate the effectiveness of its therapeutic products and to begin large-scale production in preparation for the first human clinical trials. These steps are expected to enable the company to triple its number of employees by 2028. Article content Since its unveiling less than two years ago, the Inspire project has sparked genuine enthusiasm within the life sciences ecosystem. Initially hosting the headquarters of Cellcarta, it has since brought together various Montreal universities and the Montreal Clinical Research Institute (IRCM). The project gained international recognition by being awarded the title of Future Office Project of the Year at the prestigious World Architecture Festival (WAF). This life sciences hub is already attracting a community of forward-thinking researchers and entrepreneurs focused on innovation, and continues to welcome companies from around the world seeking to thrive in its dynamic environment. Article content Located in the heart of downtown Montreal, Inspire Bio Innovations offers an ideal location with easy access via public and active transportation and proximity to major highways. This life sciences innovation hub is strategically located near a vibrant community of research centres and top-tier researchers, including MILA, CR-CHUM, CR-CUSUM, IRCM, and IRIC. This proximity will significantly enhance interactions and knowledge sharing. Additionally, being close to major hospitals like CHUM and MUHC will streamline the execution of local clinical studies. These factors make Inspire Bio Innovations highly attractive for retaining current talent and recruiting global experts. Article content 'We are excited to pursue our activities within Inspire Bio Innovations, a cutting-edge hub that fosters exchanges and interactions with top-tier researchers and innovative entrepreneurs. The collaborative environment created by Jadco is ideal for advancing the development of therapies with the potential to transform the treatment of patients with cancer or autoimmune diseases, both in Québec and globally.'—Patrick Tremblay, Ph.D., Chief Operating Officer at Ability Biotherapeutics. Article content 'We firmly believe that Inspire Bio Innovations is the ideal hub for nurturing the next generation of researchers and innovators who will propel the entire life sciences ecosystem forward. Montreal possesses all the attributes necessary to strengthen its role as one of the most dynamic and promising international centres in this field. This new space, dedicated to innovation and precision medicine, will unite talented teams whose work will continue this tradition while facilitating the commercialization of discoveries.'—Normand Rivard, Managing Partner, Life Sciences and Innovation, Jadco Group. Article content 'Ability Biotherapeutics' addition to the Inspire Bio Innovations scientific hub once again demonstrates the excellence of this innovation centre dedicated to scientific research. This new partnership strengthens the project's leading role in biotechnology. We are delighted to see this promising collaboration take shape in Plateau-Mont-Royal.'—Luc Rabouin, Leader of Projet Montréal. Article content About Ability Biotherapeutics Ability Biotherapeutics is the next-generation biotherapeutics company developing logic-gated antibodies with exceptional contextual selectivity and stability, driving safer, more effective immunotherapies for cancer and autoimmune diseases. Its proprietary platform, AbiLeap™, uses generative AI powered by one of the largest and exclusively held, therapeutically relevant human antibody databases, providing distinct insights for sequence space exploration. Combining AI with in vitro display and screening technologies, AbiLeap™ generates fully human antibodies that are conditionally activated and multi-specific, directing therapeutic targeting to specific cells and disease sites. This approach enables solutions for indications with high unmet clinical needs by reducing toxicity and significantly broadening the therapeutic window, maximizing treatment benefits. Ability's experienced team is committed to revolutionizing targeted therapeutics to transform patient outcomes and redefine industry standards. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
Yahoo
29-04-2025
- Business
- Yahoo
Ability Biotherapeutics Moves to Inspire Bio Innovations in Montreal, Pioneering the New Generation of Targeted Antibodies
MONTREAL, April 29, 2025--(BUSINESS WIRE)--Ability Biotherapeutics, a Quebec-based leader in antibody therapeutics, is proud to announce its new location at Inspire Bio Innovations. The company will occupy the 6th floor of Phase 2 in the transformative redevelopment of the former Montreal Chest Institute, marking a significant step in its growth within Montreal's thriving life sciences ecosystem. The project's first phase is scheduled for completion this summer, with the second phase, including Ability's new space, expected to wrap up by the end of 2026. Ability Biotherapeutics is pioneering a new generation of targeted antibody therapies for cancer and autoimmune diseases, powered by its proprietary generative AI-based AbiLeap™ platform. Ability is advancing multiple drug discovery programs, with three lead programs now entering optimization and development as it prepares for preclinical studies. Taking advantage of Inspire Bio Innovations' dynamic environment, Ability plans to complete preclinical studies to demonstrate the effectiveness of its therapeutic products and to begin large-scale production in preparation for the first human clinical trials. These steps are expected to enable the company to triple its number of employees by 2028. Since its unveiling less than two years ago, the Inspire project has sparked genuine enthusiasm within the life sciences ecosystem. Initially hosting the headquarters of Cellcarta, it has since brought together various Montreal universities and the Montreal Clinical Research Institute (IRCM). The project gained international recognition by being awarded the title of Future Office Project of the Year at the prestigious World Architecture Festival (WAF). This life sciences hub is already attracting a community of forward-thinking researchers and entrepreneurs focused on innovation, and continues to welcome companies from around the world seeking to thrive in its dynamic environment. Located in the heart of downtown Montreal, Inspire Bio Innovations offers an ideal location with easy access via public and active transportation and proximity to major highways. This life sciences innovation hub is strategically located near a vibrant community of research centres and top-tier researchers, including MILA, CR-CHUM, CR-CUSUM, IRCM, and IRIC. This proximity will significantly enhance interactions and knowledge sharing. Additionally, being close to major hospitals like CHUM and MUHC will streamline the execution of local clinical studies. These factors make Inspire Bio Innovations highly attractive for retaining current talent and recruiting global experts. Quotes "We are excited to pursue our activities within Inspire Bio Innovations, a cutting-edge hub that fosters exchanges and interactions with top-tier researchers and innovative entrepreneurs. The collaborative environment created by Jadco is ideal for advancing the development of therapies with the potential to transform the treatment of patients with cancer or autoimmune diseases, both in Québec and globally."—Patrick Tremblay, Ph.D., Chief Operating Officer at Ability Biotherapeutics. "We firmly believe that Inspire Bio Innovations is the ideal hub for nurturing the next generation of researchers and innovators who will propel the entire life sciences ecosystem forward. Montreal possesses all the attributes necessary to strengthen its role as one of the most dynamic and promising international centres in this field. This new space, dedicated to innovation and precision medicine, will unite talented teams whose work will continue this tradition while facilitating the commercialization of discoveries."—Normand Rivard, Managing Partner, Life Sciences and Innovation, Jadco Group. "Ability Biotherapeutics' addition to the Inspire Bio Innovations scientific hub once again demonstrates the excellence of this innovation centre dedicated to scientific research. This new partnership strengthens the project's leading role in biotechnology. We are delighted to see this promising collaboration take shape in Plateau-Mont-Royal."—Luc Rabouin, Leader of Projet Montréal. About Ability BiotherapeuticsAbility Biotherapeutics is the next-generation biotherapeutics company developing logic-gated antibodies with exceptional contextual selectivity and stability, driving safer, more effective immunotherapies for cancer and autoimmune diseases. Its proprietary platform, AbiLeap™, uses generative AI powered by one of the largest and exclusively held, therapeutically relevant human antibody databases, providing distinct insights for sequence space exploration. Combining AI with in vitro display and screening technologies, AbiLeap™ generates fully human antibodies that are conditionally activated and multi-specific, directing therapeutic targeting to specific cells and disease sites. This approach enables solutions for indications with high unmet clinical needs by reducing toxicity and significantly broadening the therapeutic window, maximizing treatment benefits. Ability's experienced team is committed to revolutionizing targeted therapeutics to transform patient outcomes and redefine industry standards. About Jadco GroupFounded in 1987, Jadco Group is a Quebec-based real estate company that designs, develops and builds signature residential and industrial projects specifically for the life sciences ecosystem. Renowned for the high quality of its projects, which meet the most stringent ESG standards, Jadco and its institutional partners have accumulated over $1.2 billion in investments in Québec. The company also acts as a property manager. View source version on Contacts Information and interviews: Stéphanie BilodeauCommunication AdvisorAbility Biotherapeuticsstephanie@ Sign in to access your portfolio
Associated Press
29-04-2025
- Business
- Associated Press
Ability Biotherapeutics Moves to Inspire Bio Innovations in Montreal, Pioneering the New Generation of Targeted Antibodies
MONTREAL--(BUSINESS WIRE)--Apr 29, 2025-- Ability Biotherapeutics, a Quebec-based leader in antibody therapeutics, is proud to announce its new location at Inspire Bio Innovations. The company will occupy the 6th floor of Phase 2 in the transformative redevelopment of the former Montreal Chest Institute, marking a significant step in its growth within Montreal's thriving life sciences ecosystem. The project's first phase is scheduled for completion this summer, with the second phase, including Ability's new space, expected to wrap up by the end of 2026. Ability Biotherapeutics is pioneering a new generation of targeted antibody therapies for cancer and autoimmune diseases, powered by its proprietary generative AI-based AbiLeap™ platform. Ability is advancing multiple drug discovery programs, with three lead programs now entering optimization and development as it prepares for preclinical studies. Taking advantage of Inspire Bio Innovations' dynamic environment, Ability plans to complete preclinical studies to demonstrate the effectiveness of its therapeutic products and to begin large-scale production in preparation for the first human clinical trials. These steps are expected to enable the company to triple its number of employees by 2028. Since its unveiling less than two years ago, the Inspire project has sparked genuine enthusiasm within the life sciences ecosystem. Initially hosting the headquarters of Cellcarta, it has since brought together various Montreal universities and the Montreal Clinical Research Institute (IRCM). The project gained international recognition by being awarded the title of Future Office Project of the Year at the prestigious World Architecture Festival (WAF). This life sciences hub is already attracting a community of forward-thinking researchers and entrepreneurs focused on innovation, and continues to welcome companies from around the world seeking to thrive in its dynamic environment. Located in the heart of downtown Montreal, Inspire Bio Innovations offers an ideal location with easy access via public and active transportation and proximity to major highways. This life sciences innovation hub is strategically located near a vibrant community of research centres and top-tier researchers, including MILA, CR-CHUM, CR-CUSUM, IRCM, and IRIC. This proximity will significantly enhance interactions and knowledge sharing. Additionally, being close to major hospitals like CHUM and MUHC will streamline the execution of local clinical studies. These factors make Inspire Bio Innovations highly attractive for retaining current talent and recruiting global experts. Quotes 'We are excited to pursue our activities within Inspire Bio Innovations, a cutting-edge hub that fosters exchanges and interactions with top-tier researchers and innovative entrepreneurs. The collaborative environment created by Jadco is ideal for advancing the development of therapies with the potential to transform the treatment of patients with cancer or autoimmune diseases, both in Québec and globally.'—Patrick Tremblay, Ph.D., Chief Operating Officer at Ability Biotherapeutics. 'We firmly believe that Inspire Bio Innovations is the ideal hub for nurturing the next generation of researchers and innovators who will propel the entire life sciences ecosystem forward. Montreal possesses all the attributes necessary to strengthen its role as one of the most dynamic and promising international centres in this field. This new space, dedicated to innovation and precision medicine, will unite talented teams whose work will continue this tradition while facilitating the commercialization of discoveries.'—Normand Rivard, Managing Partner, Life Sciences and Innovation, Jadco Group. 'Ability Biotherapeutics' addition to the Inspire Bio Innovations scientific hub once again demonstrates the excellence of this innovation centre dedicated to scientific research. This new partnership strengthens the project's leading role in biotechnology. We are delighted to see this promising collaboration take shape in Plateau-Mont-Royal.'—Luc Rabouin, Leader of Projet Montréal. View source version on CONTACT: Information and interviews: Stéphanie Bilodeau Communication Advisor Ability Biotherapeutics [email protected] KEYWORD: NORTH AMERICA CANADA INDUSTRY KEYWORD: ONCOLOGY HEALTH TECHNOLOGY HEALTH TECHNOLOGY ARTIFICIAL INTELLIGENCE BIOTECHNOLOGY SOURCE: Ability Biotherapeutics Copyright Business Wire 2025. PUB: 04/29/2025 07:45 AM/DISC: 04/29/2025 07:44 AM
